Interaction of GB Virus C/Hepatitis G Virus Synthetic Peptides with Lipid Langmuir Monolayers and Large Unilamellar Vesicles

On the role of surrounding regions in the fusion peptide in dengue virus infection

Dengue virus infection depends on its fusion with the host membrane, where the binding occurs through interaction between proteins on the virus cell surface and specific viral receptors on target membranes. This process is mediated by the fusion peptide located between residues 98 and 112 (DRGWGNGCGLFGKGG) that forms a loop in domain II of dengue E glycoprotein. In this study, we evaluated the role of fusion peptide surrounding regions (88-97 and 113-123) of the Dengue 2 subtype on its interaction with the membrane and fusion activity. These sequences are important to stabilize the fusion peptide loop and increase fusion activity. Three peptides, besides the fusion peptide, were synthesized by SPPS using the Fmoc chemical approach. The first contains the fusion peptide and the C-terminal region of the loop (sequence 98-123); another contains the N-terminal region (88-112) and the larger peptide contains both regions (88-123). The peptides were able to interact with a model membrane. Differences in morphology of the monolayer promoted by the peptides were assessed by Brewster Angle Microscopy (BAM). Our data indicated that the C-terminal region of fusion peptide loop is more efficient in promoting fusion and interacting with the membrane than the N-terminal sequence, which is responsible for the electrostatic initial interaction. We propose a 2-step mechanism for the interaction of the dengue virus fusion peptide with the host membrane, where the N-terminal sequence docks electrostatically on the headgroups and then the C-terminal interacts via hydrophobic forces in the acyl chains.

Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a Modified Cell-Penetrating Peptide

Autosomal dominantly inherited genetic disorders such as corneal dystrophies are amenable to allele-specific gene silencing with small interfering RNA (siRNA). siRNA delivered to the cornea by injection, although effective, is not suitable for a frequent long-term treatment regimen, whereas topical delivery of siRNA to the cornea is hampered by the eye surface's protective mechanisms. Herein we describe an attractive and innovative alternative for topical application using cell-penetrating peptide derivatives capable of complexing siRNA non-covalently and delivering them into the cornea. Through a rational design approach, we modified derivatives of a cell-penetrating peptide, peptide for ocular delivery (POD), already proved to diffuse into the corneal layers. These POD derivatives were able to form siRNA-peptide complexes (polyplexes) of size and ζ-potential similar to those reported able to undergo cellular internalization. Successful cytoplasmic release and gene silencing in vitro was obtained when an endosomal disruptor, chloroquine, was added. A palmitoylated-POD, displaying the best delivery properties, was covalently functionalized with trifluoromethylquinoline, an analog of chloroquine. This modified POD, named trifluoromethylquinoline-palmitoyl-POD (QN-Palm-POD), when complexed with siRNA and topically applied to the eye in vivo, resulted in up to 30% knockdown of luciferase reporter gene expression in the corneal epithelium. The methods developed within represent a valid standardized approach that is ideal for screening of a range of delivery formulations.

Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide

New therapeutic alternatives to fight against the spread of HIV-1 are based on peptides designed to inhibit the early steps of HIV-1 fusion in target cells. However, drawbacks, such as bioavailability, short half-life, rapid clearance, and poor ability to cross the physiological barriers, make such peptides unattractive for the pharmaceutical industry. Here we developed, optimized, and characterized polymeric nanoparticles (NPs) coated with glycol chitosan to incorporate and release an HIV-1 fusion inhibitor peptide (E1) inside the vaginal mucosa. The NPs were prepared by a modified double emulsion method, and optimization was carried out by a factorial design. In vitro, ex vivo, and in vivo studies were carried out to evaluate the optimized formulation. The results indicate that the physicochemical features of these NPs enable them to incorporate and release HIV fusion inhibitor peptides to the vaginal mucosa before the fusion step takes place.

Physicochemical characterisation of four peptide sequences related to thrombospondin-1B

Thrombospondin-1 (TSP-1) is a protein involved in angiogenesis and tumor metastasis. In a previous study, a tridecapeptide sequence of TSP-1B [KRFKQDGGWSHWG] was synthesized and its biological activity was determined as well as the activity of three related sequences TSPB-(E), TSPB-(S), and TSPB-(Abu)(6). These peptides were tested for activity on the cell growth of three human carcinoma cells lines and only TSPB-(Abu)(6) increased proliferation of MCF7 and HT-29. The main aim of this study was to perform physicochemical measurements, in a comparative way, to determine if the differences in activity could be related to physicochemical properties. Peptides were characterised by HPLC capacity factors, UV, fluorescence, and CD spectra (either in buffer solution or in the presence of lipid vesicles), surface activity, and aggregation. Moreover, the interaction of these peptides with phospholipids was determined through their penetration in monolayers of DPPC, PG, or PS as well as their miscibility in mixed monolayers. Besides, using liposomes as model membranes, the affinity of these peptides for phosphatidylcholine was measured with vesicles labeled with fluorescent markers (TMA-DPH, laurdan, pyrene). Results show that these molecules are highly hydrophilic and their surface activity is low. Mixed monolayers indicate that there is almost no miscibility. Besides, its presence does not modify noticeably the microviscosity of bilayers. Moreover, UV and fluorescence spectra of peptides were not affected by the presence of lipids in the media but CD spectra recorded in TFE/water (1/1) resulted in small changes for TSPB, TSPB-(E), and TSPB-(S) peptides. On the contrary CD spectra of TSPB-(Abu)(6) derivatives were clearly much more sensitive to the polarity of the environment. According to these data the biological activity of peptide with a cyclic aspartimide moiety at position 6 could be related to a specific conformational change in the peptide chain promoted by a hydrophobic membrane-like environment.

Insight into the mechanism of antimicrobial conjugated polyelectrolytes: lipid headgroup charge and membrane fluidity effects

The interactions of antimicrobial cationic conjugated polyelectrolytes (CPEs) with two model membranes, liposomes and lipid monolayers at the air-water interface, have been investigated by fluorescence emission, fluorescence quenching, pressure-area isotherm, and dynamic light scattering measurements. This study continues the evaluation of the antimicrobial mechanism of a cationic poly(phenylene ethynylene) (PPE)-based CPE (polymer 1), which contains a 2,5-thienylene moiety in the repeat unit. To this end, the interactions of polymer 1 with lipids with varying headgroup charge and acyl chain length have been examined. Our results show that the cationic polymer 1 can efficiently associate with and insert into anionic phosphatidylglycerol (PG) membranes. However, polymer 1 does not exhibit any interactions with zwitterionic lipid membranes composed of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) lipids. Polymer 1's selective affinity toward anionic lipids over zwitterionic lipids makes it an attractive antimicrobial agent with low toxicity. The interactions of polymer 1 with lipid membranes of different fluidity were studied by varying the surface pressure of lipid monolayers and by adjusting the temperature of liposomes. We observe that increasing membrane fluidity enhances both the conformational changes of polymer 1 upon associating with lipid membranes and the extent of polymer 1 insertion into lipid monolayers. We also find that the thickness of the lipid bilayers, modulated by acyl chain length, affects the extent of polymer 1 incorporation into the lipid bilayer.

Insight into the mechanism of antimicrobial poly(phenylene ethynylene) polyelectrolytes: interactions with phosphatidylglycerol lipid membranes

The interactions of antimicrobial poly(phenylene ethynylene) (PPE)-based cationic conjugated polyelectrolytes (CPEs) with lipid membranes were investigated to gain insight into the mechanism of their biocidal activity. Three model membrane systems comprising negatively charged phosphatidylglycerol (PG) lipids were used to mimic the bacterial cell membrane, including unilamellar lipid vesicles in aqueous solution, lipid bilayer coated silica microspheres, and lipid monolayers at the air-water interface. Two PPE CPEs, one containing a thiophene moiety on the PPE repeat unit and the second containing a diazabicyclooctane (DABCO) moiety on the pendant side chain, were chosen, since the former exhibits distinct dark biocidal activity and the latter shows strong light-activated antimicrobial activity but little dark biocidal activity. The interactions of these two PPE polymers with lipid membranes were characterized in detail by CPE fluorescence spectral changes, fluorescence resonance energy transfer (FRET), fluorescence quenching, monolayer insertion, and dynamic light scattering assays. Both PPE polymers exhibit affinity for the anionic lipid membrane systems. Their concomitant association and insertion into the membrane leads to conformational changes of the PPE polymer from an aggregated state to a more extended state, as evidenced by the polymer's enhanced fluorescence and FRET between the polymer and rhodamine incorporated in the lipid membrane. In comparison, the thiophene polymer exhibits stronger interactions with PG lipid membranes than the DABCO-containing polymer. The former induces a larger fluorescence enhancement, shows faster transfer across the lipid membrane, and inserts more readily and to a higher extent into lipid monolayers. The observed differences between the two PPE polymers in their interactions with the lipid membrane may stem from their structural differences, as the DABCO-containing polymer has a much bulkier and larger pendant group on its side chain. The higher degree of membrane interaction and insertion, and subsequent membrane disorganization, of the thiophene polymer may account for its dark biocidal activity.

GB virus type C interactions with HIV: the role of envelope glycoproteins

GB virus C/hepatitis G virus (GBV-C/HGV) is the most closely related human virus to hepatitis C virus (HCV). GBV-C is lymphotropic and not associated with any known disease, although it is associated with improved survival in HIV-infected individuals. In peripheral blood mononuclear cells, GBV-C induces the release of soluble ligands for HIV entry receptors (RANTES, MIP-1a, MIP-1b and SDF-1), suggesting that GBV-C may interact with lymphocytes to induce a chemokine and/or cytokine milieu that is inhibitory to HIV infection. Expression of GBV-C envelope glycoprotein E2 in CD4+ T cells or addition of recombinant E2 to CD4 cells recapitulates the HIV inhibition seen with GBV-C infection. Like HCV E2, GBV-C E2 is predicted to be post-translationally processed in the endoplasmic reticulum and is involved with cell binding. The C-termini of GBV-C E1 and E2 proteins contain predicted transmembrane domains sharing features with HCV TM domains. To date, cellular receptor(s) for GBV-C E2 have not been identified. GBV-C E2-mediated HIV inhibition is dose-dependent and HIV replication is blocked at the binding and/or entry step. In addition, a putative GBV-C E2 fusion peptide interferes with HIV gp41 peptide oligomerization required for HIV-1 fusion, further suggesting that GBV-C E2 may inhibit HIV entry. Additional work is needed to identify the GBV-C E2 cellular receptor, characterize GBV-C E2 domains responsible for HIV inhibition, and to examine GBV-C E2-mediated fusion in the context of the entire envelope protein or viral-particles. Understanding the mechanisms of action may identify novel approaches to HIV therapy.